BioWorld

March 8, 2005

CTI Tumbles 47 Percent On Missed Endpoint For Xyotax

Cell Therapeutics Inc. lost almost half of its value Monday, following news that Xyotax missed the primary endpoint in its Stellar 3 pivotal trial in non-small-cell lung cancer patients. (BioWorld Today) Read More

Celgene's Revlimid Phase III Data Beat Specified Endpoint

To Better Characterize Iressa, Biomarker Studies Under Way

Sirtris' Series B Gets $27M For Class III HDAC Research

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 3, 2026